clinical trials

News

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

Sales & Marketing

12 Questions with Chris Venezia

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales.

News

Nuvalent chases after Nuvation in ROS1 lung cancer

New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

News

ADA: Vertex closer to weaning type 1 diabetics off insulin

A cell therapy developed by Vertex Pharma has allowed 10 of 12 patients with type 1 diabetes to control their blood sugar without insulin.

News

Roche's Hemlibra follow-up set for phase 3 in haemophilia A

Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.

Nektar eyes pivotal trials for eczema drug cast off by Lilly

Biogen races into phase 3 with Spinraza follow-up

12 Questions with Chris Venezia

Nuvalent chases after Nuvation in ROS1 lung cancer

ADA: Vertex closer to weaning type 1 diabetics off insulin

Roche's Hemlibra follow-up set for phase 3 in haemophilia A

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks